{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:24Z","timestamp":1790035044872,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.urolonc.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T13:28:19Z","timestamp":1506691699000},"page":"12.e1-12.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"36","author":[{"given":"Jacques","family":"Raphael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Thawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.09.004_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.09.004_bib4","article-title":"Moving towards dose individualization of tyrosine kinase inhibitors","author":"Klumpen","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2017.09.004_bib5","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","article-title":"A population pharmaco- kinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients","volume":"15","author":"Houk","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.09.004_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints inpatients with cancer: results of a pharmacokinetic\/pharmacodynamics meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.urolonc.2013.10.004","article-title":"Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature","volume":"32","author":"Bjarnason","year":"2014","journal-title":"Urol Oncol"},{"issue":"11-12Suppl7","key":"10.1016\/j.urolonc.2017.09.004_bib8","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.5489\/cuaj.4293","article-title":"Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?","volume":"10","author":"Bjarnason","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2017.09.004_bib9","first-page":"35","article-title":"Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer","author":"Bjarnason","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.09.004_bib11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.09.004_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1535-7163.MCT-14-0208","article-title":"Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications","volume":"14","author":"Adelaiye","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2017.09.004_bib13","article-title":"Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma","author":"Ornstein","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2017.09.004_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2017.09.004_bib15","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib16","unstructured":"https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"10.1016\/j.urolonc.2017.09.004_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajco.12360","article-title":"Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma","volume":"11","author":"Mitchell","year":"2015","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clgc.2016.05.007","article-title":"Clinical experience of escalated sunitinib dose in select patients with metastatic renal cell carcinoma","volume":"15","author":"Shi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2017.09.004_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1464-410X.2011.10421.x","article-title":"Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment","volume":"109","author":"Mancuso","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.09.004_bib20","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1158\/1078-0432.CCR-07-0111","article-title":"Hypoxia inducible factor-1 independent pathways in tumor angiogenesis","volume":"13","author":"Mizukami","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.09.004_bib21","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","article-title":"Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance","volume":"17","author":"Gotink","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.09.004_bib22","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s10637-011-9764-8","article-title":"Sorafenib exposure decreases over time in patients with hepatocellular carcinoma","volume":"30","author":"Arrondeau","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.urolonc.2017.09.004_bib23","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","article-title":"Variability of sorafenib toxicity and exposure over time: a pharmacokinetic\/pharmacodynamic analysis","volume":"17","author":"Boudou-Rouquette","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2017.09.004_bib24","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/0008-5472.CAN-14-3687","article-title":"Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma","volume":"75","author":"Kuczynski","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2017.09.004_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clgc.2016.04.005","article-title":"Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma","volume":"14","author":"Rini","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2017.09.004_bib26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.09.004_bib27","article-title":"The effect of stereotactic ablative radiotherapy on time to change of systemic therapy in extra-cranial renal cell carcinoma metastases","volume":"34","author":"Wang","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917304672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917304672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:49Z","timestamp":1761041389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917304672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1078143917304672"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.09.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}